Visceral Leishmaniasis: Clinical Trials

8 trials for Visceral Leishmaniasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 8 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 38Completed 8

Follow Visceral Leishmaniasis: new trials by email Literature Review of Visceral Leishmaniasis trials Research Report on Visceral Leishmaniasis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
Miltefosine, Paromomycin, Sodium stibogluconate - Visceral Leishmaniasis
Phase 3CompletedDrugs for Neglected Diseases4392018-01-242024-02-29
Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.
Liposomal Amphotericin B, Miltefosine - Visceral Leishmaniasis
Phase 3CompletedDrugs for Neglected Diseases592014-07-012019-04-08
Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh
Liposomal amphotericin B, liposomal amphotericin B + miltefosine, liposomal amphotericin B + paromomycin - Visceral Leishmaniasis
Phase 3CompletedDrugs for Neglected Diseases6022010-05-012016-01-21
Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis
Amphotericin B Deoxycholate, Ambisome + Miltefosine, Ambisome and Paromomycin - Visceral Leishmaniasis
Phase 3CompletedDrugs for Neglected Diseases6342008-06-012010-02-11
An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis
Paromomycin - Visceral Leishmaniasis
Phase 3CompletedBanaras Hindu University3292008-02-012008-09-12
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
Liposomal Amphotericin B, amphotericin B deoxycholate - Visceral Leishmaniasis
Phase 3CompletedBanaras Hindu University4002008-02-012009-04-03
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
Sodium Stibogluconate, Paromomycin sulphate, SSG and Paromomycin sulphate - Visceral Leishmaniasis
Phase 3CompletedDrugs for Neglected Diseases11422004-11-012016-03-22
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
Paromomycin sulfate, Amphotericin B - Visceral Leishmaniasis
Phase 3CompletedPATH6672003-06-012014-10-03

Narrower conditions

Leishmaniasis, Visceral (8)

Broader conditions

Euglenozoa Infections (8)  ·  Infections (8)  ·  Leishmaniasis (8)  ·  Parasitic Diseases (8)  ·  Protozoan Infections (8)  ·  Vector Borne Diseases (8)

Interventions

Paromomycin (6)  ·  liposomal amphotericin B (4)  ·  miltefosine (4)  ·  Antimony Sodium Gluconate (2)  ·  amphotericin B, deoxycholate drug combination (2)  ·  Amphotericin B (1)

Sponsors

Drugs for Neglected Diseases (5)  ·  Banaras Hindu University (2)  ·  PATH (1)

Countries

India (4)  ·  Ethiopia (3)  ·  Kenya (2)  ·  Sudan (2)  ·  Uganda (2)  ·  Bangladesh (1)

Top investigators

Shyam Sundar, MD (2)  ·  Ahmed M Musa, MD, Prof (1)  ·  Dr. S.K. Bhattacharya (1)  ·  Ermias Diro, Dr. MD (1)  ·  Farrokh Modabber (1)  ·  Jane Mbui, MD (1)  ·  Joseph Olobo, MD, Prof (1)  ·  Manica Balasegaram (1)  ·  Prof C.P. Thakur (1)  ·  Prof S. Sundar (1)  ·  Prof T.K. Jha (1)  ·  Rezika Mohammed, MD (1)  ·  Ridwanur Rahman, MD (1)

Results publications

PMID 17582067, PMID 19663597, PMID 20147716, PMID 21049063, PMID 21255828, PMID 22724029, PMID 28558062, PMID 30653490, PMID 30789910, PMID 36164254